Key result
SGLT2 inhibitors and lipid-lowering agents may mitigate cancer therapy cardiotoxicity despite inconsistent neurohormonal blockade.
Why the study?
Cancer therapy-related cardiovascular toxicity is an increasingly recognised challenge in oncology because life-saving cancer treatments can cause significant cardiac complications.
Do pharmacological strategies prevent cancer therapy-related cardiovascular toxicity in high-risk cancer patients?
Do pharmacological strategies prevent cancer therapy-related cardiovascular toxicity in high-risk cancer patients?
This review highlights the current landscape of pharmacological strategies, including emerging roles for SGLT2 inhibitors and GLP-1 receptor agonists, in preventing cancer therapy-related cardiovascular toxicity.
No takes yet. Share an insight, caveat, or question.
clause):**.
Cancer therapy-related cardiovascular toxicity is an increasingly recognised challenge in modern oncology, as life-saving treatments can lead to significant cardiac complications. This review explores the current landscape of medical strategies aimed at preventing cardiotoxicity across a broad range of cancer therapies. High-risk patients are identified based on clinical and treatment-related risk factors, necessitating proactive risk stratification. Neurohormonal blockade strategies have shown promising although not universally consistent effects against therapy-induced cardiovascular toxicity. As well, lipid-lowering agents may offer additional cardiovascular protection through both lipid modulation and anti-inflammatory properties. Moreover, emerging evidence supports the potential of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in mitigating cardiotoxic effects, calling for dedicated clinical trials. In the meantime, the 2022 European Society of Cardiology guidelines provided a structured approach to integrating pharmacological and non-pharmacological protective strategies in cardio-oncology. Challenges remain in standardising care due to heterogeneous data and limited large-scale trials. Multidisciplinary collaboration, ongoing translational research and personalised medicine are crucial to optimising cardiovascular outcomes in patients with cancer.
Camilli et al. (2026) studied this question. Neurohormonal blockade shows promising but inconsistent cardioprotection; lipid-lowering agents and emerging therapies like SGLT2 inhibitors may mitigate cancer therapy-related cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: